Cellular versus acellular grafts for diabetic foot ulcers: Altering the protocol to improve recruitment to a comparative efficacy trial

Catherine N. Tchanque-Fossuo, Sara E. Dahle, Hadar Lev-Tov, Chin Shang Li, R. Rivkah Isseroff

Research output: Contribution to journalArticle

3 Scopus citations


Diabetic foot ulcers (DFUs) have a substantial impact on public health. The standard of care (SOC) for DFUs consists of a multi-disciplinary approach involving glycemic control, wound care with debridement of necrotic tissue, application of a moist dressing, infection control, use of off-loading devices, and patient education. New therapeutic devices aim to target the extracellular matrix (ECM) that is impaired in DFU; however, there is insufficient data on the effectiveness of such therapies along with lack of evidence on their long-term effectiveness. We hypothesized that there is no differ-ence in healing between the cellular matrix and an acellular matrix relative to SOC. To test this hypothesis, we conducted a randomized, single-blind clinical trial in patients with nonhealing DFUs that included 3 treatment arms: (1) SOC, (2) SOC plus a bioengineered ECM with living fibroblasts, and (3) SOC plus a bioengineered ECM devoid of cells. Our trial currently is closed for enrollment, as we have reached our target population size. Amendments to the protocol were made to help reach this threshold.

Original languageEnglish (US)
Pages (from-to)E18-E21
Issue number5
StatePublished - Nov 1 2017


ASJC Scopus subject areas

  • Dermatology

Cite this